Barclays raised the firm’s price target on Tenet Healthcare (THC) to $171 from $161 and keeps an Overweight rating on the shares following the Q1 report. The firm says strong fundamentals and accelerating share repurchase overshadow policy and macro risks, and conservative guidance “is a useful buffer.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare’s Strategic Expansion and Strong Financial Performance Highlighted by Conservative Guidance and Robust Margins
- Tenet Healthcare Reports Strong Q1 2025 Results
- Tenet Healthcare’s Strong Q1 Performance Amid Policy Uncertainty
- Tenet Healthcare’s Strong Performance and Strategic Focus Justify Buy Rating
- Morning Movers: Hims & Hers skyrockets following obesity pact with Novo Nordisk